IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS RECEIVING VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY

Introduction: We reported superior efficacy for venetoclax + rituximab (VenR) vs bendamustine + rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) in the MURANO study (NCT02005471), with significant progression-free survival (PFS) benefit and sustained undetectable minimal residual disease (uMRD), irrespective of historical risk factors for poor response. This analysis explores the clinical impact on outcome of major...